Security
Soligenix Inc. Warrant · SNGXW
SNGXWNASDAQWarrantHistorical · closed Dec 15, 2021CIK 812796Updated Nov 3, 2026
Name history
SOLIGENIX, INC. · through Nov 2, 2026DOR BIOPHARMA INC · through Sep 29, 2009ENDOREX CORP · through Oct 24, 2001IMMUNOTHERAPEUTICS INC · through Apr 30, 1996
Current security for this SEC filerSNGX · NASDAQ
SNGXW price & chart
Historical security
This listing closed Dec 15, 2021. Live provider charts are shown only for current listings.
Current security: SNGX
About the company
We are a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. We maintain two active business segments: Specialized BioTherapeutics and Public Health Solutions.
In the news
No coverage from other publishers is available.
Recent filings
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders · Other Events
Items 5.03, 5.07, 8.01, 9.01
424B3 filing
424B3 filing
424B3 filing
424B3 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 11,293,917Source | 10,476,979Source | 10,499,470Source | 5,760,647Source | 9,865,079Source | 6,922,640Source | 7,746,120Source | 8,058,385Source | 9,235,521Source | 8,966,483Source | 9,797,326Source | 14,279,717Source |
| Property, Plant and Equipment, NetUSD | 7,812Source | 7,162Source | 6,577Source | 8,114Source | 8,751Source | 7,675Source | 5,505Source | 10,339Source | 8,772Source | 6,113Source | 11,927Source | 18,481Source |
| Current assets: | ||||||||||||
| Assets, CurrentUSD | 10,880,913Source | 10,306,892Source | 10,171,786Source | 5,320,452Source | 9,662,872Source | 6,565,248Source | 7,640,742Source | 7,818,387Source | 8,849,007Source | 8,828,630Source | 9,507,320Source | 13,853,152Source |
| Operating Lease, Right-of-Use AssetUSD | 382,415Source | 140,148Source | 298,330Source | 409,304Source | 170,679Source | 326,940Source | 77,096Source | 200,569Source | 354,965Source | 108,963Source | 229,834Source | 340,987Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 3,695,941Source | 4,541,791Source | 3,853,913Source | 3,931,696Source | 6,400,303Source | 3,832,735Source | 4,133,682Source | 7,290,013Source | 3,943,396Source | 4,848,412Source | 7,274,904Source | 16,750,500Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 9,861Source | 2,295Source | 21,637Source | 3,505Source | 1,542Source | 10,518Source | 3,183Source | 10,524Source | 10,086Source | 2,514Source | 10,378Source | 2,909Source |
| Additional Paid in CapitalUSD | 249,697,269Source | 236,878,806Source | 256,441,582Source | 241,403,653Source | 232,699,640Source | 250,909,695Source | 240,770,981Source | 228,353,208Source | 250,287,382Source | 238,040,520Source | 228,193,977Source | 217,064,964Source |
| Retained Earnings (Accumulated Deficit)USD | -242,154,943Source | -230,983,386Source | -249,863,451Source | -239,623,996Source | -229,264,005Source | -247,876,097Source | -237,207,515Source | -227,619,503Source | -245,051,132Source | -233,970,752Source | -225,704,176Source | -219,563,446Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 45,789Source | 37,473Source | 45,789Source | 45,789Source | 27,599Source | 45,789Source | 45,789Source | 24,143Source | 45,789Source | 45,789Source | 22,243Source | 24,747Source |
| Stockholders' Equity Attributable to ParentUSD | 7,597,976Source | 5,935,188Source | 6,645,557Source | 1,828,951Source | 3,464,776Source | 3,089,905Source | 3,897,933Source | 768,372Source | 5,292,125Source | 4,118,071Source | 2,522,422Source | -2,470,826Source |
| Liabilities and EquityUSD | 11,293,917Source | 10,476,979Source | 10,499,470Source | 5,760,647Source | 9,865,079Source | 6,922,640Source | 7,746,120Source | 8,058,385Source | 9,235,521Source | 8,966,483Source | 9,797,326Source | 14,279,717Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 3,422,021Source | 4,530,247Source | 3,671,839Source | 3,629,107Source | 6,354,612Source | 3,619,310Source | — | 7,210,888Source | 3,699,275Source | 4,848,412Source | 6,152,108Source | 16,516,873Source |
| Operating Lease, Liability, CurrentUSD | 111,134Source | 132,114Source | 120,515Source | 108,814Source | 128,592Source | 117,235Source | 79,125Source | 125,143Source | 114,023Source | 111,862Source | 121,765Source | 108,948Source |
| Accounts Payable, CurrentUSD | 1,206,796Source | 891,227Source | 1,407,298Source | 649,955Source | 1,698,225Source | 828,658Source | 599,688Source | 1,436,728Source | 1,115,497Source | 667,896Source | 1,111,226Source | 3,865,796Source |
| Operating Lease, Liability, NoncurrentUSD | 273,920Source | 11,544Source | 182,074Source | 302,589Source | 45,691Source | 213,425Source | — | 79,125Source | 244,121Source | — | 111,862Source | 233,627Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 2,031,272Source | 1,363,235Source | 2,059,974Source | 2,783,149Source | 1,701,806Source | 2,630,416Source | 3,404,332Source | 2,602,665Source | 1,981,630Source | 2,359,339Source | 2,418,002Source | 2,307,746Source |
| Long-term DebtUSD | — | — | — | — | — | — | — | — | — | 0Source | 1,010,934Source | — |
| Preferred Stock, Value, Issued | — | — | — | — | —Source | — | — | —Source | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -2,824,965Source | -2,951,268Source | -11,080,380Source | -8,266,576Source | -6,140,730Source | -13,798,339Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 121,208Source | 63,599Source | 587,583Source | 329,815Source | 370,182Source | 333,389Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -2,357,723Source | -1,847,012Source | -10,266,553Source | -8,403,618Source | -8,604,109Source | -12,649,021Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | -5,883Source | — | — | -13,073Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | 5,883Source | — | — | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 451,000Source | 1,324,669Source | 10,389,075Source | 7,762,089Source | 3,663,506Source | 76,821Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -1,906,723Source | -522,343Source | 116,639Source | -626,644Source | -4,913,457Source | -12,684,282Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 10,525,335Source | 9,840,177Source | 9,811,141Source | 5,097,670Source | 6,029,430Source | 7,297,171Source | 7,936,153Source | 7,819,514Source | 8,446,158Source | 13,359,615Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | 35,044Source | 35,044Source | 227,735Source | 552,058Source | 857,411Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | — | — | — | 14,885Source | 27,146Source | -99,009Source |
| Additional Financial Items | ||||||||||||
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | — | — | — | — | 12,518Source | 41,538Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -2,815Source | 575Source | 68Source | -8,045Source | -1,516Source | -788Source | -11,814Source | 1,591Source | 1,483Source | -30,549Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | — | 575Source | — | — | — | — | — | 1,591Source | -1,483Source | -30,549Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | 58,443Source | — | — | — | — | — | -393,791Source | — |
| General and Administrative ExpenseUSD | — | — | 996,604Source | 896,547Source | 1,125,372Source | 1,086,865Source | 1,102,538Source | 1,084,828Source | 4,359,663Source | 4,215,908Source | 4,482,552Source | 6,692,904Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -506,615Source | -409,114Source | -1,767,803Source | -1,154,935Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,530,947Source | -1,719,381Source | -1,987,354Source | -2,701,976Source | -2,824,965Source | -2,951,268Source | -11,080,380Source | -8,266,576Source | -6,140,730Source | -13,798,339Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -2,530,947Source | -1,719,381Source | -1,987,354Source | -2,701,976Source | -2,824,965Source | -2,951,268Source | -11,080,380Source | -8,266,576Source | -6,140,730Source | -13,798,339Source |
| Nonoperating Income (Expense)USD | — | — | 49,536Source | 145,855Source | 112,109Source | 61,903Source | 59,873Source | 75,240Source | 258,481Source | 763,807Source | -210,593Source | -714,370Source |
| Operating ExpensesUSD | — | — | 2,580,483Source | 1,865,236Source | 2,099,463Source | 2,763,879Source | 2,884,838Source | 3,026,508Source | 11,845,476Source | 9,439,497Source | 7,795,251Source | 14,636,993Source |
| Other Nonoperating Income (Expense)USD | — | — | -2,815Source | 67,019Source | 58,511Source | -7,920Source | -1,516Source | -788Source | -11,689Source | 549,832Source | 43,223Source | 5,921Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | — | — | — | — | — | — | — | — | 973,000Source | 596,000Source | 421,000Source | 427,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | — | 119,371Source | 839,359Source | 948,911Source |
| Cost of Goods and Services Sold | — | — | — | — | — | — | — | — | — | —Source | —Source | —Source |
| Operating Income (Loss)USD | — | — | -2,580,483Source | -1,865,236Source | -2,099,463Source | -2,763,879Source | -2,884,838Source | -3,026,508Source | -11,845,476Source | -9,439,497Source | -7,697,940Source | -14,238,904Source |
| Other Nonoperating Income (Expense)USD | — | — | -2,815Source | 67,019Source | 58,511Source | -7,920Source | -1,516Source | -788Source | -11,689Source | 549,832Source | 43,223Source | 5,921Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -2,530,947Source | -1,719,381Source | -1,987,354Source | -2,701,976Source | -2,824,965Source | -2,951,268Source | -11,586,995Source | -8,675,690Source | -7,908,533Source | -14,953,274Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -506,615Source | -409,114Source | -1,767,803Source | -1,154,935Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,530,947Source | -1,719,381Source | -1,987,354Source | -2,701,976Source | -2,824,965Source | -2,951,268Source | -11,080,380Source | -8,266,576Source | -6,140,730Source | -13,798,339Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.58Source | -0.78Source | -0.12Source | -0.82Source | -0.28Source | -0.97Source | -2.14Source | -4.98Source | -0.79Source | -4.81Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.58Source | -0.78Source | -0.12Source | -0.82Source | -0.28Source | -0.97Source | -2.14Source | -4.98Source | -0.79Source | -4.81Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 4,329,649Source | 2,203,929Source | 15,951,949Source | 3,278,677Source | 10,164,898Source | 3,049,625Source | 5,188,799Source | 1,660,413Source | 7,758,036Source | 2,871,345Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 4,329,649Source | 2,203,929Source | 15,951,949Source | 3,278,677Source | 10,164,898Source | 3,049,625Source | 5,188,799Source | 1,660,413Source | 7,758,036Source | 2,871,345Source |
| Additional Financial Items | ||||||||||||
| Cost, Depreciation and AmortizationUSD | — | — | — | — | — | — | 1,098Source | 608Source | 3,224Source | 5,814Source | 6,554Source | 24,562Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -2,815Source | 575Source | 68Source | -8,045Source | -1,516Source | -788Source | -11,814Source | 1,591Source | 1,483Source | -30,549Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | — | 575Source | — | — | — | — | — | 1,591Source | -1,483Source | -30,549Source |
| General and Administrative ExpenseUSD | — | — | 996,604Source | 896,547Source | 1,125,372Source | 1,086,865Source | 1,102,538Source | 1,084,828Source | 4,359,663Source | 4,215,908Source | 4,482,552Source | 6,692,904Source |
| Gross ProfitUSD | — | — | — | — | — | — | — | — | — | — | 97,311Source | 398,089Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 52,351Source | 78,836Source | 53,598Source | 69,823Source | 61,389Source | 76,028Source | 270,170Source | 213,975Source | -49,129Source | -822,611Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -2,530,947Source | -1,719,381Source | -1,987,354Source | -2,701,976Source | -2,824,965Source | -2,951,268Source | -11,080,380Source | -8,266,576Source | -6,140,730Source | -13,798,339Source |
| Nonoperating Income (Expense)USD | — | — | 49,536Source | 145,855Source | 112,109Source | 61,903Source | 59,873Source | 75,240Source | 258,481Source | 763,807Source | -210,593Source | -714,370Source |
| Operating ExpensesUSD | — | — | 2,580,483Source | 1,865,236Source | 2,099,463Source | 2,763,879Source | 2,884,838Source | 3,026,508Source | 11,845,476Source | 9,439,497Source | 7,795,251Source | 14,636,993Source |
| Research and Development ExpenseUSD | — | — | 1,583,879Source | 968,689Source | 974,091Source | 1,677,014Source | 1,782,300Source | 1,941,680Source | 7,485,813Source | 5,223,589Source | 3,312,699Source | 7,944,089Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | — | — | — | — | — | — | — | — | 973,000Source | 596,000Source | 421,000Source | 427,000Source |
Offerings
Registration 333-271049
Registration 333-276511
Registration 333-280993
Registration 333-290413
- Gross proceeds
- 7498515.0
- Net proceeds
- 7011111.0
- Deal price
- 1.35
- Shares
- 5554456
- Offering amount
- $1.62
- Offering price
- $1.35
- Ticker
- SNGX
Filing attachments
sngx-20260428xex99d1.htm · 8-K · 2026-04-28
EX-99.1 2 sngx-20260428xex99d1.htm EX-99.1 EXHIBIT 99.1 Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma Princeton, NJ - April 28, 2026 - Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Data Monitoring Committee completed the in…
Read attachment ↗sngx-20251231xex4d1.htm · 10-K · 2026-03-31
EXHIBIT 4.1 SOLIGENIX, INC. DESCRIPTION OF SECURITIES The following description of the terms of our securities is not complete and is qualified in its entirety by reference to our Certificate of Incorporation, as amended (the “Certificate of Incorporation”) and our Bylaws, as amended (the “Bylaws”), both of which are filed as exhibits to our Annual Reports on Form 10-K. Under our Certificate of Incorporation and Bylaws, we are authorized to issue 75,350,000 shares of capital stock, consistin…
Read attachment ↗sngx-20260212xex99d1.htm · 8-K · 2026-02-12
EXHIBIT 99.1 Soligenix Details Recent Progress and Upcoming Milestones Princeton, NJ - February 12, 2026 - Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber. The content of this letter is provided below. Dear Friends and Shareholder…
Read attachment ↗sngx-20250925xex4d1.htm · 8-K · 2025-09-29
EX-4.1 2 sngx-20250925xex4d1.htm EX-4.1 EXHIBIT 4.1 PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK SOLIGENIX, INC. Warrant Shares: ________ Original Issuance Date: September 25, 2025 ──────────────────────────────────────────────────────────────────────────── THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations o…
Read attachment ↗sngx-20250925xex4d2.htm · 8-K · 2025-09-29
EX-4.2 3 sngx-20250925xex4d2.htm EX-4.2 EXHIBIT 4.2 WARRANT TO PURCHASE SHARES OF COMMON STOCK SOLIGENIX, INC. Warrant Shares: Original Issuance Date: September 25, 2025 ─────────────────────────────────────────────────────────────────── THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter…
Read attachment ↗sngx-20250925xex99d1.htm · 8-K · 2025-09-29
EX-99.1 6 sngx-20250925xex99d1.htm EX-99.1 EXHIBIT 99.1 Soligenix Announces Pricing of $7.5 Million Public Offering PRINCETON, N.J., September 26, 2025 - Soligenix, Inc. (Nasdaq: SNGX) (“Soligenix” or the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced the pricing of its “reasonable best efforts” public offering with existing and certain healthcare focused inst…
Read attachment ↗